After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, CTMX falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of CytomX Therapeutics Inc is $56.87M. A total of 0.72 million shares were traded on the day, compared to an average of 1.83M shares.
In the most recent transaction, McCarthy Sean A. sold 37,656 shares of CTMX for 0.60 per share on Mar 18 ’25. After the transaction, the CEO now owns 995,195 company shares. In a previous transaction on Mar 18 ’25, Ogden Christopher sold 8,551 shares at 0.60 per share. CTMX shares that Chief Financial Officer owns now total 201,026.
Among the insiders who sold shares, Chu Yu-Waye disposed of 4,025 shares on Mar 18 ’25 at a per-share price of $0.60. This resulted in the Chief Medical Officer holding 135,725 shares of CTMX after the transaction. In another insider transaction, ROWLAND LLOYD A sold 10,203 shares at $0.60 per share on Mar 18 ’25. Company shares held by the General Counsel now total 120,594.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, CTMX has a high of $5.85 and a low of $0.40.
As of this writing, CTMX has an earnings estimate of $0.13 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of $0.25 per share and a lower estimate of -$0.08.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. CTMX’s latest balance sheet shows that the firm has $305.23M in Cash & Short Term Investments as of fiscal 2021. There were $21.67M in debt and $77.87M in liabilities at the time. Its Book Value Per Share was -$0.01, while its Total Shareholder’s Equity was -$459.00k.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CTMX is Buy with a score of 4.14.
